Evidence map›Paper›PMID 39815170›Full record

ArticleNanomedicine (London, England)2025

Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.

Monica Mossenta, Monica Argenziano, Sara Capolla, Davide Busato, Paolo Durigutto, Alessandro Mangogna, Maurizio Polano, Daniele Sblattero, Roberta Cavalli, Paolo Macor and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Monica MossentaExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.
Monica ArgenzianoDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Sara CapollaExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.
Davide BusatoExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.ORCID 0000-0001-8127-3948
Paolo DuriguttoDepartment of Life Sciences, University of Trieste, Trieste, Italy.
Alessandro MangognaDepartment of Life Sciences, University of Trieste, Trieste, Italy.
Maurizio PolanoExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.
Daniele SblatteroDepartment of Life Sciences, University of Trieste, Trieste, Italy.
Roberta CavalliDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Paolo MacorDepartment of Life Sciences, University of Trieste, Trieste, Italy.
Giuseppe ToffoliExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.
Michele Dal BoExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.ORCID 0000-0001-8668-7621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting agent, such as the humanized anti-GPC3 antibody GC33 (condrituzumab), could be attached to their surface. Here, we investigated the use of idarubicin-loaded CS-NBs for HCC treatment and a GC33-derived minibody (that we named 4A1) to enhance CS-NB delivery.

methodsVarious CS-NB formulations were prepared with or without 4A1 conjugation and idarubicin loading.

resultsCS-NBs had a positive charge and a diameter of about 360 nm. In

conclusionsCS-NBs loaded with idarubicin can be a useful drug delivery strategy for HCC treatment.

Indexed as

Carcinoma, HepatocellularChitosanIdarubicinLiver NeoplasmsNanoparticlesAnimalsCell Line, TumorCell SurvivalDrug CarriersDrug Delivery SystemsHumansMiceMice, NudeTissue DistributionXenograft Model Antitumor AssaysChitosanDrug CarriersIdarubicinantibody conjugation, glypican 3chitosandrug deliveryHepatocellular carcinomaidarubicinnanobubbles

Identifiers

PMID39815170
PMCPMC11792799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.